AstraZeneca has announced that it has received marketing authorization from the European Commission for its Fluenz nasal spray vaccine for the prevention of seasonal flu in children under 18 years old down to 24 months old. Fluenz is marketed in the US as FluMist by MedImmune. Read the company’s press release.
EC approves Fluenz intranasal flu vaccine for use in children
published on
Featured event:
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany
October 28, 2026: Webinar: From Guidance to Practice: Navigating Revised FDA PSGs for Inhaled Products, online
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
